InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Werner Milton H., Chairman & CEO. Insider active across 2 companies, notably Inhibikase Therapeutics, Inc.. Aggregated, 10 disclosures have been published. Total volume traded: €72k. The latest transaction was filed on 27 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations10 total
€4,5475,000 shares@ €0.90930.0020% mcap3.1% of flow
Common Stock
SEC:0000899243-22-020094:0·
Ideal exit: 21 Feb 2023 (T+270)
€5,67210,000 shares@ €0.56720.0025% mcap3.9% of flow
Common Stock
SEC:0000899243-22-019229:0·
Ideal exit: 14 Feb 2023 (T+270)
€38,81221,853 shares@ €1.776136.2% of flow
Common Stock
SEC:0001104659-22-001168·
€38,81221,853 shares@ €1.77610.017% mcap26.8% of flow
Common Stock
SEC:0001104659-22-001168:0·
€30,72717,569 shares@ €1.74890.013% mcap21.2% of flow
Common Stock
SEC:0001104659-21-141628:0·
Ideal exit: 14 Aug 2022 (T+270)
€30,72717,569 shares@ €1.748928.7% of flow
Common Stock
SEC:0001104659-21-141628·
Ideal exit: 14 Aug 2022 (T+270)
€37,69821,853 shares@ €1.725135.2% of flow
Common Stock
SEC:0000899243-21-033598·
€37,69821,853 shares@ €1.72510.017% mcap26.0% of flow
Common Stock
SEC:0000899243-21-033598:0·
€13,75243,707 shares@ €0.31460.0060% mcap9.5% of flow
Common Stock
SEC:0000899243-21-019788:0·
€13,75243,707 shares@ €0.3146100.0% of flow
Common Stock
SEC:0000899243-21-019788·
10 of 10 declarations
About Werner Milton H.
Milton H. Werner is the President and CEO of Inhibikase Therapeutics, Inc. He leads the company with a strategic vision, overseeing operations and research and development initiatives. Milton is responsible for implementing corporate strategies and managing stakeholder relationships. His experience in the biopharmaceutical sector is a valuable asset for the leadership of Inhibikase.
